Международные рекомендации по диагностике и лечению эозинофильного гранулематоза с полиангиитом – 2015
https://doi.org/10.14412/1995-4484-2016-129-137
Аннотация
В 2015 г. при участии экспертов из пяти стран Европы, США и Канады были подготовлены рекомендации по диагностике и лечению эозинофильного гранулематоза с полиангиитом, ранее известного как синдром Черджа–Строс, которые аккумулировали научные достижения и клинический опыт, накопленный к настоящему времени. Предложенные рекомендации не должны рассматриваться как окончательные стандарты, но призваны стать основанием для выбора персонифицированной стратегии ведения больных эозинофильным гранулематозом с полиангиитом и послужить отправной точкой для дальнейших исследований. Целями публикации являются общая характеристика основных положений рекомендаций и обсуждение некоторых дискуссионных проблем.
Об авторах
Т. В. Бекетова
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва
Россия
Россия
115522 Москва, Каширское шоссе, 34А
М. Ю. Волков
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва
Россия
Россия
115522 Москва, Каширское шоссе, 34А
Список литературы
1. Jennette JC, Falk RJ, Bacon PA, еt аl. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715
2. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150
3. Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306-9. doi: 10.1093/rheumatology/ket445
4. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310-7. doi: 10.1136/ard.2008.088096
5. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214-23. doi: 10.1056/NEJMoa1108735
6. Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51(1):92-9. doi: 10.1002/art.20077
7. Jones R, Cohen Tervaert J, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-20. doi: 10.1056/NEJMoa0909169
8. Stone J, Merkel P, Spiera R, et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-32. doi: 10.1056/NEJMoa0909905
9. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545-53. doi: 10.1016/j.ejim.2015.04.022
10. Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011-7. doi: 10.1136/annrheumdis-2012-201531
11. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094-100. doi: 10.1002/art.1780330806
12. Lanham J, Elkon K, Pusey C, Hughes G. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine. 1984;63:65-81. doi: 10.1097/00005792- 198403000-00001
13. Marchand E, Reynaud-Gaubert M, Lauque D, et al. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d'Etudes et de Recherche sur les Maladies «Orphelines» Pulmonaires (GERM“O”P). Medicine (Baltimore). 1998;77(5):299-312. doi: 10.1097/00005792-199809000-00001
14. Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classiёcation of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607-12. doi: 10.1016/j.jaci.2012.02.019
15. Taylor MR, Keane CT, O’Connor P, et al. The expanded spectrum of toxocaral disease. Lancet. 1988;1(8587):692-5. doi: 10.1016/S0140-6736(88)91486-9
16. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis. 2001;33(7):1040-7. doi: 10.1086/322707
17. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest. 2009;135(3):805-26. doi: 10.1378/chest.08-2586
18. Gotlib J. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 2015 Nov;90(11):1077-89. doi: 10.1002/ajh.24196
19. Emmi G, Silvestri E, Marconi R, et al. First report of FIP1L1- PDGFRα-positive eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 2015 Sep;54(9):1751-3. doi: 10.1093/rheumatology/kev242
20. Emmi G, Vaglio A. Comment on: First report of FIP1L1- PDGFRα-positive eosinophilic granulomatosis with polyangiitis: reply. Rheumatology (Oxford). 2016 Feb;55(2):386. doi: 10.1093/rheumatology/kev397
21. Roufosse F, Garaud S, de Leval L. Lymphoproliferative disorders associated with hypereosinophilia. Semin Hematol. 2012 Apr;49(2):138-48. doi: 10.1053/j.seminhematol.2012.01.003
22. Jin JJ, Butterfield JH, Weiler CR. Hematologic malignancies identified in patients with hypereosinophilia and hypereosinophilic syndromes. J Allergy Clin Immunol Pract. 2015;3(6):920-5. doi: 10.1016/j.jaip.2015.06.009
23. Туркина АГ, Немченко ИС, Челышева ЕЮ и др. Клинические рекомендации по диагностике и лечению миелопролиферативных заболеваний с эозинофилией и идиопатического гиперэозинофильного синдрома. II Конгресс гематологов России, апрель 2014 г. Доступно по ссылке: http://26reg.roszdravnadzor.ru/i/upload/images/2015/9/18/1442567111.77654-1-5547.pdf [Turkina AG, Nemchenko IS, Chelysheva EYu, et al. Clinical guidelines for the diagnosis and treatment of myeloproliferative diseases with eosinophilia and idiopathic hypereosinophilic syndrome. II Congress of Hematology Russia, in April 2014 Available from: http://26reg.roszdravnadzor.ru/i/upload/images/2015/9/18/14425 67111.77654-1-5547.pdf].
24. Choi HK, Liu S, Merkel PA, et al. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. J Rheumatol. 2001;28(7):1584-90.
25. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926-35. doi: 10.1002/art.21250
26. Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270- 81. doi: 10.1002/art.37721
27. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115:284-90. doi: 10.1016/S0002-9343(03)00359-0
28. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632-8. doi: 10.7326/0003-4819-143-9- 200511010-00006
29. Grayson PC, Monach PA, Pagnoux C, et al. Vasculitis Clinical Research Consortium. Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54(8):1351-9. doi: 10.1093/rheumatology/keu427
30. Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2012;30(1 Suppl. 70):S62-5. doi: 10.1016/j.jaci.2013.11.026
31. Hurst S, Chizzolini C, Dayer JM, et al. Usefulness of serumeosinophil cationic protein (ECP) in predicting relapse of Churg and Strauss vasculitis. Clin Exp Rheumatol. 2000;18(6):784-5.
32. Dallos T, Heiland GR, Strehl J, et al. CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum. 2010;62(11):3496-503. doi: 10.1002/art.27678
33. Vaglio A, Strehl JD, Manger B, et al. IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis. 2012;71(3):390-3. doi: 10.1136/ard.2011.155382
34. Zwerina J, Bach C, Martorana D, et al. Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford). 2011;50(10):1823-7. doi: 10.1093/rheumatology/keq445
35. Polzer K, Karonitsch T, Neumann T, et al. Eotaxin-3 is involved in Churg-Strauss syndrome – a serum marker closely correlating with disease activity. Rheumatology (Oxford). 2008;47(6):804-8. doi: 10.1093/rheumatology/ken033
36. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75:17-28. doi: 10.1097/00005792-199601000-00003
37. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma – summary report 2007. J Allergy Clin Immunol. 2007;120:S94-S138. doi: 10.1016/j.jaci.2007.09.029
38. Стрижаков ЛА, Моисеев СВ, Коган ЕА. Поражение сердца при системных васкулитах: патогенетические звенья, значение факторов риска развития сердечно-сосудистых осложне- ний и диагностика. Терапевтический архив. 2014;12(2):35-42 [Strizhakov LA, Moiseev SV, Kogan EA. Heart disease in systemic vasculitis: pathogenetic links of the value of risk factors for cardiovascular disease and diagnosis. Terapevticheskii Arkhiv. 2014;12(2):35-42 (In Russ.)].
39. Hazebroek MR, Kemna MJ, Schalla S, et al. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. Int J Cardiol. 2015 Nov 15;199:170-9. doi: 10.1016/j.ijcard.2015.06.087
40. Samson M, Puechal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60-9. doi: 10.1016/j.jaut.2013.03.003
41. Marmursztejn J, Guillevin L, Trebossen R, et al. Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. Rheumatology (Oxford). 2013;52(4):642-50. doi: 10.1093/rheumatology/kes155
42. Marmursztejn J, Cohen P, Duboc D, et al. Cardiac magnetic resonance imaging in Churg-Strauss syndrome. Impact of immunosuppressants on outcome assessed in a prospective study on 8 patients. Clin Exp Rheumatol. 2010;28(1 Suppl 57):8-13.
43. Marmursztejn J, Vignaux O, Cohen P, et al. Impact of cardiacmagnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients. Clin Exp Rheumatol. 2009;27(1 Suppl 52): S70-6.
44. Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore). 2009;88(4):236-43. doi: 10.1097/MD.0b013e3181af35a5
45. Dennert RM, van Paassen P, Schalla S, et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum. 2010;62(2):627-34. doi: 10.1002/art.27263
46. Pagnoux C, Mahr A, Cohen P, et al. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore). 2005;84(2):115-28. doi: 10.1097/01.md.0000158825.87055.0b
47. Robson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;54(3):471-81. doi: 10.1093/rheumatology/keu366
48. Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90:19-27. doi: 10.1097/MD.0b013e318205a4c6
49. De Groot K, Harper L, Jayne D, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670-80. doi: 10.7326/0003-4819-150-10- 200905190-00004
50. Harper L, Morgan M, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71:955-60. doi: 10.1136/annrheumdis-2011-200477
51. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-80. doi: 10.1056/NEJMoa1404231
52. Chung JB, Armstrong K, Schwartz JS, et al. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 2000;43(8):1841-8. doi: 10.1002/1529- 0131(200008)43:83.0.CO;2-Q
53. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med. 1995;151(3 Pt 1):795-9. doi: 10.1164/ajrccm.151.3.7881673
54. Somers EC, Marder W, Christman GM, et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005;52(9):2761-7. doi: 10.1002/art.21263
55. Jayne D, Rasmussen N, Andrassy K, et al. European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44. doi: 10.1056/NEJMoa020286
56. Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003;42(6):1149-53. doi: 10.1053/j.ajkd.2003.08.015
57. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;14:73. doi: 10.1186/1745-6215-14-73
58. Munoz SA, Gandino IJ, Orden AO, Allievi A. Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. Reumatol Clin. 2015;11(3):165-9. doi: 10.1016/j.reuma.2014.08.005
59. Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2014 Dec 2. pii: annrheumdis-2014- 206095. doi: 10.1136/annrheumdis-2014-206095
60. Fanouriakis A, Kougkas N, Vassilopoulos D, et al. Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence. Semin Arthritis Rheum. 2015;45(1):60-6. doi: 10.1016/j.semarthrit.2015.03.004
61. Bouldouyre M-A, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis. 2009;68(4):606. doi: 10.1136/ard.2008.093773
62. Tsurikisawa N, Taniguchi M, Saito H, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2004;92(1):80-7. doi: 10.1016/S1081-1206(10)61714-0
63. Rutberg SA, Ward DE, Roth BJ. Churg-Strauss syndrome and pregnancy: successful treatment with intravenous immunoglobulin. J Clin Rheumatol. 2002;8(3):151-6. doi: 10.1097/00124743- 200206000-00007
64. Koike H, Akiyama K, Saito T, et al. Research Group for IVIg for EGPA/CSS in Japan. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, doubleblind trial. J Neurol. 2015;262(3):752-9. doi: 10.1007/s00415-014- 7618-y
65. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med. 1998;129(5):370-4. doi: 10.7326/0003-4819-129-5-199809010- 00004
66. Metzler C, Csernok E, Gross WL, et al. Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clin Exp Rheumatol. 2010;28(1 Suppl 57):24- 30.
67. Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000;117(3):708-13. doi: 10.1378/chest.117.3.708
68. Harrold LR, Patterson MK, Andrade SE, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmacoepidemiol Drug Saf. 2007;16(6):620-6. doi: 10.1002/pds.1353
69. Hauser T, Mahr A, Metzler C, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. 2008;63(8):677-82. doi: 10.1136/thx.2007.087825
70. Nathani N, Little MA, Kunst H, et al. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax. 2008;63(10):883-8. doi: 10.1136/thx.2007.093955
71. Vanoli M, Gambini D, Scorza R. A case of Churg-Strauss vasculitis after hepatitis B vaccination. Ann Rheum Dis. 1998;57(4):256-7. doi: 10.1136/ard.57.4.256
72. Guillevin L, Guittard T, Bletry O, et al. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung. 1987;165(3):165-72. doi: 10.1007/BF02714432
73. Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore). 2005;84(5):323-30. doi: 10.1097/01.md.0000180793.80212.17
74. Kostianovsky A, Charles P, Alves JF, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol. 2012;30(1 Suppl. 70):S83-9.
75. Herlyn K, Gross WL, Reinhold-Keller E. Longitudinale Effekte des strukturierten Patientenschulungsprogramms fur Vaskulitispatienten. Z Rheumatol. 2008;67(3):206-10. doi: 10.1007/s00393-008-0290-9
76. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73. doi: 10.1183/09031936.00202013
77. Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009;68(4):564-7. doi: 10.1136/ard.2008.099051
78. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29(18):2276-315. doi: 10.1093/eurheartj/ehn310
79. Patterson MF, Borish L, Kennedy JL. The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review. J Asthma Allergy. 2015 Nov 3;8:125-34. doi: 10.2147/JAA.S74178
80. Gioffredi A, Maritati F, Oliva E, et al. Eosinophilic granulomatosis with polyangiitis: an overview. Front Immunol. 2014 Nov 3;5:549. doi: 10.3389/fimmu.2014.00549
81. Jakiela B, Szczeklik W, Plutecka H, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology (Oxford). 2012 Oct;51(10):1887- 93. doi: 10.1093/rheumatology/kes171
82. Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336-43. doi: 10.1016/j.jaci.2010.03.028
83. Moosig F, Gross WL, Herrmann K, et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med. 2011;155(5):341-3. doi: 10.7326/0003-4819-155-5- 201109060-00026
84. Bjermer L, Lemiere C, Maspero J, et al. A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. Eur Respir J. 2014;44 Suppl 58:299.
85. Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016 Jan 8. pii:S0954-6111(16)30003-8. doi: 10.1016/j.rmed.2016.01.003
86. Josselin-Mahr L, Werbrouck-Chiraux A, Garderet L, et al. Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase? Rheumatology (Oxford). 2014 Feb;53(2):378-9. doi: 10.1093/rheumatology/ket261
87. Erre GL, Pardini S, Cuccuru L, et al. Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis? Joint Bone Spine. 2015 Jan;82(1):72-3. doi: 10.1016/j.jbspin.2014.06.004
Рецензия
Для цитирования:
Бекетова Т.В., Волков М.Ю. Международные рекомендации по диагностике и лечению эозинофильного гранулематоза с полиангиитом – 2015. Научно-практическая ревматология. 2016;54(2):129-137. https://doi.org/10.14412/1995-4484-2016-129-137
For citation:
Beketova T.V., Volkov M.Yu. THE 2015 INTERNATIONAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. Rheumatology Science and Practice. 2016;54(2):129-137. (In Russ.) https://doi.org/10.14412/1995-4484-2016-129-137
Просмотров: 1048
Послать статью по эл. почте 